ITGAM and neoplasm: Apart from suppressed tumor angiogenesis (Figure 7D), we found that the percentage of M2 TAMs (CD45+ CD11b+ F4/80+ CD206+ cells) were significantly fewer in LY2801653 treatment group (28.82 ± 1.76) compared with control group (53.96 ± 6.62) (P < .01) (Figure 7E).